Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Persisting new nodules in incidence rounds of the NELSON CT lungcancer screening study The US guidelines recommend low-dose CT (LDCT) lungcancer screening for high-risk individuals. New solid nodules after baseline screening are common and have a high lungcancer probability. Currently, no evidence exists concerning the risk stratification of non-resolving new solid nodules at first LDCT screening after initial detection.In the Dutch-Belgian Randomized LungCancer Screening (NELSON) trial (...) nodules were resolving, leaving 356 (52%) participants with a non-resolving new solid nodule, of whom 25 (7%) were diagnosed with lungcancer. At first screening after initial detection, volume doubling time (VDT), volume, and VDT combined with a predefined ≥200 mm3 volume cut-off had high discrimination for lungcancer (VDT, area under the curve (AUC): 0.913; volume, AUC: 0.875; VDT and ≥200 mm3 combination, AUC: 0.939). Classifying a new solid nodule with either ≤590 days VDT or ≥200 mm3 volume
Short-Term Readmissions After Open, Thoracoscopic, and Robotic Lobectomy for LungCancer Based on the Nationwide Readmissions Database Readmission after surgery is an established surrogate indicator of quality of care. We aimed to compare short-term readmission rates and patient outcomes between open, video-assisted thoracoscopic (VATS), and robotic lobectomies in the Nationwide Readmissions Database (NRD).Adults who underwent open, VATS, or robotic lobectomy for lungcancer from 2010 to 2014 (...) were evaluated. Propensity-matched analysis was used to assess differences in readmission characteristics, GDP-adjusted cost, and mortality.Of the 129,539 lobectomies for lungcancer, 74,493 (57.5%) were open, 48,185 (37.2%) VATS, and 6861 (5.3%) robotic. Open surgery was associated with significantly higher readmission rate (10.5 vs 9.3%, p < 0.001), mortality (2 vs 1.2%, p < 0.001), index hospitalization cost [$21,846 (16,158-31,034) vs $20,779 (15,619-27,920), p < 0.001], and length of stay [6
Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell LungCancer: ECOG-ACRIN 2511 Study Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy against small-cell lungcancer (SCLC) in preclinical studies. We evaluated the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage SCLC (ES-SCLC).Patients with ES-SCLC, stratified by sex and serum
<0.01 for interaction). This association was strong and consistent across all histological subtypes, except for adenocarcinoma, which was not strongly associated with hsCRP concentration regardless of smoking status (odds ratio for adenocarcinoma overall 0.97, 95% confidence interval 0.94 to 1.01). The association between circulating hsCRP concentration and the risk of lungcancer was strongest in the first two years of follow-up for former and current smokers. Including hsCRP concentration (...) in a risk model, in addition to smoking based variables, did not improve risk discrimination overall, but slightly improved discrimination for cancers diagnosed in the first two years of follow-up.Former and current smokers with higher circulating hsCRP concentrations had a higher risk of lungcancer overall. Circulating hsCRP concentration was not associated with the risk of lungadenocarcinoma. Circulating hsCRP concentration could be a prediagnostic marker of lungcancer rather than a causal risk
A Model-Based Cost-Effectiveness Analysis of an Exercise Program for LungCancer Survivors Following Curative-Intent Treatment. The cost-effectiveness of exercise interventions in lungcancer survivors is unknown. We performed a model-based cost-effectiveness analysis of an exercise intervention in lungcancer survivors.We used Markov modeling to simulate the impact of the Lifestyle Interventions and Independence for Elders (LIFE) exercise intervention compared to usual care for stage I-IIIA (...) lungcancer survivors following curative-intent treatment. We calculated and considered incremental cost-effectiveness ratios (ICERs) <$100,000/quality-adjusted life-year (QALY) as cost-effective and assessed model uncertainty using sensitivity analyses.The base-case model showed that the LIFE exercise program would increase overall cost by $4,740 and effectiveness by 0.06 QALYs compared to usual care and have an ICER of $79,504/QALY. The model was most sensitive to the cost of the exercise program
Management of anlotinib-related adverse events in patients with advanced non-small cell lungcancer: Experiences in ALTER-0303. Anlotinib is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, and stem cell factor receptor (c-Kit). In the phase III ALTER-0303 trial (Clinical Trial Registry ID: NCT 02388919), anlotinib significantly improved overall survival versus placebo in advanced (...) non-small cell lungcancer patients who had received at least two previous chemotherapy and epidermal growth factor receptor/anaplastic lymphoma kinase targeted therapy regimens. This study summarized adverse event management in this trial.Patients were randomized (2:1) to anlotinib or placebo up to progression or intolerable toxicity. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 and managed by investigators. Key
Alectinib (Alecensa) for the treatment of patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lungcancer (NSCLC) 1 Cost-effectiveness of alectinib (Alecensa®) for the first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lungcarcinoma (NSCLC) The NCPE has issued a recommendation regarding the cost-effectiveness of alectinib (Alecensa®). Following assessment of the applicant’s submission, the NCPE recommends (...) lymphoma kinase (ALK)-positive advanced non-small cell lungcancer (NSCLC). At the same time, they also converted the conditional marketing authorisation to a standard marketing authorisation for the crizotinib failure indication (2L) which had been approved in the EU since February 2017. In April 2018, Roche Products (Ireland) Ltd submitted a dossier examining the cost-effectiveness of alectinib for the first-line treatment of ALK-positive advanced NSCLC. The authorised dose for this indication
within the Cancer Drugs Fund, as an option for untreated, metastatic, non-squamous non-small-cell lungcancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations. It is only recommended if: pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier if disease progresses and the company provides pembrolizumab according to the managed access agreement. 1.2 This recommendation is not intended to affect (...) non-squamous non-small-cell lungcarcinoma (NSCLC) in adults whose tumours have no epidermal growth factor receptor or anaplastic lymphoma kinase-positive tumour mutations' . Dosage in Dosage in the the mark marketing eting authorisation authorisation 200 mg every 3 weeks by intravenous infusion. The summary of product characteristics recommends treatment with pembrolizumab until disease progression or unacceptable toxicity. Price Price £1,315.00 per 50 mg vial (excluding VAT; British national
annually, exceeding those from any other malignancy . Lungcancer is the most common cause of cancer death in men and the second leading cause of cancer death in women, worldwide. It is the commonest cancer in Asia and is the leading cause of death in Southern, Eastern and South Eastern Asia . Fifty-one percent of the world’s lungcancer cases occur in Asia , and 21% of cancer deaths in Asia are due to lung can- cer . The number of cases and the crude and standardised inci- dence rates (...) who have never smoked being especially marked in Asian countries . A recent Korean study of 5456 cases of lungcancer in a community cancer centre showed the proportion of cases in never smokers to have increased from 19.4% between 2004 and 2008 to 25.4% be- tween 2009 and 2012 . Epidemiological data have resulted in ‘non-smoking-associ- ated lungcancer’ being considered a distinct disease entity, where speci?c molecular and genetic differences have been identi?ed between the lungcancers
ASTRO Guideline on Palliative Radiation Therapy for Non-small Cell LungCancer (NSCLC) - Update Palliative thoracic radiation therapy for non-small cell lungcancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline - Practical Radiation Oncology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Volume 8, Issue 4, Pages 245–250 Palliative thoracic radiation therapy for non-small cell lungcancer: 2018 Update (...) Accepted: February 19, 2018 ; Received: February 6, 2018 ; Abstract Purpose To revise the recommendation on the use of concurrent chemotherapy (CC) with palliative thoracic external beam radiation therapy (EBRT) made in the original 2011 American Society for Radiation Oncology guideline on palliative thoracic radiation for lungcancer. Methods and materials Based on a systematic PubMed search showing new evidence for this key question, the task force felt an update was merited. Guideline
lungcancers are epithelial tumours that develop from squamous or glandular epithelium (adenocarcinoma) . Lungcarcinoma is also referred to as bronchial carcinoma since this malignanttumour arises from the bronchial epithelium [10, 11]. It is classified into the following main histological types : ? Small cell lungcancer (SCLC; approx. 15%) ? Non-small cell lungcancer (NSCLC; approx. 85%): ? squamous cell carcinoma: spindle cell variant (40%) Extract of rapid report V18-03 Version 1.0 (...) malignanttumours in the lungMalignant lymphomas and sarcomas are canceroustumours that can arise as primary thoracic tumours or as lung metastases . Metastases to the lung often also develop in connection with carcinomas of the colon, rectum, kidney, breast, prostate, and oropharynx . Diffuse malignant pleural mesothelioma originates in the mesothelial or submesothelial cells of the pleura, peritoneum, or pericardium. More than 80% of mesotheliomas originate in the pleura. Mesothelioma
Gibbert ? Thomas Kaiser ? Petra Kohlepp ? Ulrike Lampert ? Katrin Nink Keywords: osimertinib, carcinoma – non-small-cell lung, benefit assessment, NCT02296125 Extract of dossier assessment A18-45 Version 1.0 Osimertinib (non-small cell lungcancer) 11 October 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - 1 - Executive summary of the benefit assessment Background In accordance with §35a Social Code Book (SBG) V, the Federal Joint Committee (G-BA) commissioned the Institute (...) Osimertinib (non-small cell lungcancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Osimertinib (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 October 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English- language readers. However, solely the German original text is absolutely
-small cell lungcancer (NSCLC) whose tumours express programmed cell death ligand-1 (PD-L1) on = 1% of tumour cells and whose disease did not progress following platinum-based chemoradiotherapy. Table 2 presents the research question of the benefit assessment and the ACT specified by the G-BA. Table 2 2 : Research question of the benefit assessment of durvalumab Indication ACT a Adults with locally advanced, inoperable NSCLC whose tumours express PD-L1 on = 1% of tumour cells and whose disease has (...) Durvalumab (locally advanced, unresectable NSCLC) 10 January 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - 2 - Included were adult patients with locally advanced, inoperable NSCLC (stage III according to the International Association for the Study of LungCancer [IASLC] Version 7) with no disease progression following definitive, combined, platinum-based chemoradiotherapy. In the study, 713 patients were randomized, 476 to the intervention arm and 237 to the comparator arm. In both
cancer (MK-3475- 021/KEYNOTE-021): study results [online]. In: ClinicalTrials.gov. 30.01.2019 [Accessed: 16.05.2019]. URL: https://clinicaltrials.gov/ct2/show/results/NCT02039674. Merck Sharp Dohme. A phase 1/2 study of MK-3475 (SCH900475) in combination with chemotherapy or immunotherapy in patients with locally advanced or metastatic non-small cell lungcarcinoma: study P021V03MK3475; clinical study report [unpublished]. 2018. Merck Sharp Dohme. Pembrolizumab KEYNOTE 021G trial platinum therapy (...) Pembrolizumab (non-squamous non-small cell lungcancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Pembrolizumab (nicht plattenepitheliales NSCLC, Kombinationschemotherapie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative
: hazard ratio; n: number of patients with at least one event; N: number of analysed patients; NA: not achieved; QLQ-C30: Quality of Life Questionnaire-Core 30; QLQ-LC13: Quality of Life Questionnaire-LungCancer 13; RCT: randomized controlled trial; SAE: serious adverse event; TPS: Tumour Proportion Score; VAS: visual analogue scale; vs.: versus Based on the available data, at most indications, e.g. of an added benefit, can be derived for the outcomes “symptoms” (measured with the EORTC QLQ-C30 (...) Pembrolizumab (squamous non-small cell lungcancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Pembrolizumab (plattenepitheliales NSCLC, Kombinationschemotherapie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally
Pembrolizumab (Keytruda) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lungcancer (NSCLC). DSD: Horizon Scanning in Oncology 91. Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lungcancer (NSCLC) - Repository of AIHTA GmbH English | Browse - - - Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lungcancer (NSCLC (...) ) McGahan, L. (2019): Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lungcancer (NSCLC). DSD: Horizon Scanning in Oncology 91. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 1MB Abstract Non-small cell lungcancer (NSCLC) arises when epithelial cells lining the bronchial tubes undergo aberrant cell growth due to up-regulation of programmed death (PD-1) ligands, thereby affording evasion of immune
, investigate and refer patients with symptoms that may be lungcancer according to best practice evidence. 32 ` ` Services should have clearly documented pathways and facilitate timely and streamlined referral of patients into the specialist lungcancer team for diagnosis, staging and treatment in line with the national Optimal Care Pathway. 30,31 ` ` Clearly defined evidence-based treatment pathways for patients with lungcancer should be developed according to disease stage. ` ` All patients (...) . 46. Freeman RK, Van Woerkom JM, Vyverberg A, Ascioti AJ. The effect of a multidisciplinary thoracic malignancy conference on the treatment of patients with lungcancer. European Journal of Cardio-Thoracic Surgery. 2010;38(1):1-5. 47. Pillay B, Wootten AC, Crowe H, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treatment Reviews. 2016;42:56-72. 48. Boxer MM, Vinod SK, Shafiq J
Lorlatinib (Lorbrena) - To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lungcancer Drug Approval Package: LORBRENA (lorlatinib) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: LORBRENA (lorlatinib) Company: Pfizer, Inc. Application Number: 210868 Approval Date: 11/02/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter